SEC Form 4 · accession 0001104659-17-005333
NOVELION THERAPEUTICS INC. · NVLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Sandford D Smith
Director
Period of report
Jan 27, 2017
Accepted (ET)
Jan 31, 2017 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000827809
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common SharesF1,F2 | Jan 27, 2017 | M | 456 | — | A | 1,048 | D | |
| Common Shares | Jan 27, 2017 | F | 148 | $9.38 | D | 900 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2,F3 | — | Jan 27, 2017 | M | 456 | D | — | — | Common Shares | 456 | 1,367 | D |
Explanation of responses
- F1Reflects a one-for-five share consolidation of the common shares of Novelion Therapeutics Inc. effective December 16, 2016.
- F2Each restricted stock unit represents a contingent right to receive one common share.
- F316.67% of the grant vested on each of January 27, 2016 and July 27, 2016. Subject to the Reporting Person continuing to serve as a member of the board of Novelion Therapeutics Inc., an additional 456 units will vest on July 27, 2017; an additional 456 units will vest on January 27, 2018; and an additional 455 units will vest on August 21, 2018.